Rheumatoid Arthritis in the 21st Century: Treatment Patterns and Disease Activity States

Nikiphorou, Elena; Rannio, T.; Sokka, Tuulikki

doi:10.3899/jrheum.150615

Cited by 2 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The armamentarium of bDMARDs was expanded in the second decade and medications have been made more accessible to patients with addition of biosimilars and the coverage of costs by the public health system in Europe. 7 – 9 Over the past years, following therapeutic advancements and introduction of treat-to-target concept, we have achieved significant improvement in disease activity control on the population level, particularly in RA. However, not all patients achieve optimal control of their disease activity and individualized approach to treatment of rheumatic diseases remains elusive.…”

Section: Introductionmentioning

confidence: 99%

Big data analyses and individual health profiling in the arena of rheumatic and musculoskeletal diseases (RMDs)

Cock

Myasoedova

Aletaha

et al. 2022

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Health care processes are under constant development and will need to embrace advances in technology and health science aiming to provide optimal care. Considering the perspective of increasing treatment options for people with rheumatic and musculoskeletal diseases, but in many cases not reaching all treatment targets that matter to patients, care systems bare potential to improve on a holistic level. This review provides an overview of systems and technologies under evaluation over the past years that show potential to impact diagnosis and treatment of rheumatic diseases in about 10 years from now. We summarize initiatives and studies from the field of electronic health records, biobanking, remote monitoring, and artificial intelligence. The combination and implementation of these opportunities in daily clinical care will be key for a new era in care of our patients. This aims to inform rheumatologists and healthcare providers concerned with chronic inflammatory musculoskeletal conditions about current important and promising developments in science that might substantially impact the management processes of rheumatic diseases in the 2030s.

show abstract

Section: Introductionmentioning

confidence: 99%